Skip to content

Inspection Record

Biocon Biologics Limited — FDA 483 Findings

US FDAInspected 2022-08-26Published 2022-09-23 10 findingsComputer system validationLaboratory and QC controlsEquipment and facilityAseptic processing and sterility assuranceDeviation, CAPA, and investigationCleaning validationOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Computer system validation

Computer systems used in the testing of a drug product are not of appropriate design to facilitate operations for its intended use.

2Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that components and in-process materials conform to appropriate standards of identity, strength, quality and purity.

3Equipment and facility

Your firm's facilities are not adequate to ensure the prevention ofcontamination ofequipment or product by environmental conditions that could reasonably be expected to have an adverse effect on product quality.

4Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established and followed.

5Deviation, CAPA, and investigation

Written records of investigations into unexplained discrepancies and the failure ofa batch or any of its components to meet specifications do not always include the conclusions and follow-up.

6Cleaning validation

There is a lack of assurance that your cleaning procedures for the shared product-contact process equipment in your Drug Substance and Fill-Finish product manufacturing facilities, are effective in preventing cross-contamination.

7Deviation, CAPA, and investigation

GMP Equipment is used outside its validated aceeptance criteria for critically controlled matenal, Specifically, Quality Control Stability Chambers, QC-Q13-Al-141 and QC-Q13-AI-142, located in QC Building (13, are validated for 2— 8 °C and both have had numerous excursions from their validated temperature over the past two year, Additionally, these excursions have not triggered deviations to be opened.

8Deviation, CAPA, and investigation

Deviations from written test procedures and laboratory mechanisms are not recorded and justified.

9Equipment and facility

Your firm has not established adequate procedural controls to protect the ic data acquisition and/or manufacturing control systems used for DS and DP manufacturing in your Site manufacturing facilities, Specifically, A.

10Other quality system

aot CRD IS Fo) Gel | ewrucrese en ORMAE: ALM TFTLIE: (PSA oe Th OTe Beep SEE Michael F.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2022-09-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Biocon Biologics Limited findings history — including this company's other documentsAll US FDA findings US FDA documents, 2022 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.